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a b s t r a c t
The past decade has witnessed a number of exciting developments in the ﬁeld of mitochondrial dy-
namics – a phenomenon in which changes in mitochondrial shape and movement impact on cellular
physiology and pathology. By undergoing fusion and ﬁssion, mitochondria are able to change their
morphology between elongated interconnected networks and discrete fragmented structures, respec-
tively. The cardiac mitochondria, in particular, have garnered much interest due to their unique spatial
arrangement in the adult cardiomyocyte, and the multiple roles they play in cell death and survival. In
this article, we review the role of the mitochondrial fusion and ﬁssion proteins as novel therapeutic
targets for treating cardiovascular disease.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
In the heart, the mitochondria occupy nearly one third the volume
of a cardiomyocyte – they sustain the energy required for normal
cardiac contractile function by producing up to 30 kg of adenosine
triphosphate (ATP) per day. However, the role of cardiac mitochondria
extends far beyond that of being merely the ‘powerhouse’ of the cell.
The past decade has witnessed a number of developments in the ﬁeld
of mitochondrial dynamics – a phenomenon in which changes in
mitochondrial shape and movement have been demonstrated to im-
pact on cellular physiology and pathology. Mitochondria are dynamic
organelles which are able to change their shape by undergoing fusion
to generate elongated interconnected mitochondrial networks, and
ﬁssion to produce discrete fragmented mitochondria. These processes
are under the regulation of the mitochondrial fusion and ﬁssion pro-
teins, respectively, and are essential for maintaining a healthy mi-
tochondrial network. The cardiac mitochondria, in particular, have
garnered much interest due to their unique spatial arrangement in the
adult heart, and the multiple roles they play in cell death and survival.
It is known that the actions of the mitochondrial fusion and ﬁssion
proteins extend beyond those of mediating changes in mitochondrial
shape – in this regard these pleiotropic roles may impact on their
effects in the heart and the vasculature (see Fig. 1). In this article, we
review the potential role for the mitochondrial fusion and ﬁssion
proteins as novel targets for treating cardiovascular disease.
2. Mitochondrial fusion
The fusion of two adjacent mitochondria allows the mixing of
intra-mitochondrial proteins and the replacement of damaged
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